Search

Search Constraints

You searched for: Author/Creator Renger, John J.

Search Results

1. Blood-Gene Expression Reveals Reduced Circadian Rhythmicity in Individuals Resistant to Sleep Deprivation. Issue 10 (1st October 2014)

2. Cover Picture: Discovery of 5′′‐Chloro‐N‐[(5, 6‐dimethoxypyridin‐2‐yl)methyl]‐2, 2′:5′, 3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia (ChemMedChem 2/2014). Issue 2 (February 2014)

3. Discovery of 5′′‐Chloro‐N‐[(5, 6‐dimethoxypyridin‐2‐yl)methyl]‐2, 2′:5′, 3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia. Issue 2 (27th December 2013)

4. Discovery of [11C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors. Issue 21 (1st November 2015)

5. Discovery of [11C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors. Issue 21 (1st November 2015)

6. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Issue 21 (1st November 2015)

7. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Issue 21 (1st November 2015)

8. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology. Issue 23 (1st December 2016)

9. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Issue 3 (1st February 2015)

10. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Issue 1 (1st January 2016)